A recombinant Pseudomonas aeruginosa with high rhamnolipid production and its application
By overexpressing the NADP+-dependent malate enzyme gene maeB in Pseudomonas aeruginosa, the problem of delayed NADPH regeneration rate in host cells was solved, achieving efficient production of rhamnolipids with significantly improved yield and conversion rate.
Patent Information
- Application Number
- CN202611335572.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for increasing rhamnolipin production in Pseudomonas aeruginosa by enhancing the expression of rhamnolipin synthase genes have failed to effectively address the problem of delayed NADPH regeneration rate in host cells, resulting in extended rate-limiting fatty acid synthesis and preventing efficient rhamnolipin production.
By overexpressing the NADP+-dependent malate enzyme-encoding gene maeB in Pseudomonas aeruginosa, high-level expression was achieved through strong promoter regulation, breaking the host transcriptional repression, enhancing the in situ regeneration capacity of intracellular NADPH, and synergistically replenishing pyruvate to the acetyl-CoA precursor pool, thus alleviating reducing pressure.
The yield of rhamnolipin from the recombinant strain was significantly improved, with the yield in shake flask fermentation increasing from 3.52 g/L to 4.97 g/L, and the yield in a 5.0L fermenter reaching 50.95 g/L. The substrate-product conversion rate was also improved, achieving efficient production of rhamnolipin.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of synthetic biology, genetic engineering, and metabolic engineering, and relates to a recombinant Pseudomonas aeruginosa that produces high levels of rhamnolipids and its applications. Specifically, it relates to a method that utilizes exogenous broad-host recombinant plasmids to overexpress endogenous NADP. + A recombinant *Pseudomonas aeruginosa* strain that enhances intracellular reducing power in situ by encoding a malate-dependent malate enzyme gene, thereby increasing rhamnolipid production; its construction method; and the application of this recombinant strain in the fermentation production of biosurfactants. Background Technology
[0002] Rhamnolipids (RL) are glycolipid metabolites with excellent surface activity, secreted by Pseudomonas aeruginosa and other Pseudomonas species under specific fermentation conditions. They belong to the category of water-soluble anionic biosurfactants. Their molecular structure typically consists of one or two rhamnose molecules as a core, linked by one or two long-chain β-hydroxyalkanoic acid molecules via glycosidic bonds. Rhamnolipids exhibit extremely low critical micelle concentrations (CMC), extremely high thermal stability, salt tolerance, and excellent biodegradability and ecological safety, making them promising for industrial applications in petroleum extraction, agricultural soil remediation, crop disease control, daily chemical cleaning, and pharmaceuticals.
[0003] From a biosynthetic pathway perspective, the synthesis of rhamnolipids is highly dependent on the flux of precursor substances. The glycolipid precursor dTDP-L-rhamnose is synthesized through a four-step sequential enzymatic reaction (catalyzed by an enzyme encoded by the rmlBDAC operon); while the lipid precursor β-hydroxy fatty acids are heavily dependent on the host's own fatty acid synthesis (FAS II) pathway. Finally, under the catalysis of rhamnosyltransferase (encoded by rhlAB), the glycosyl group condenses with the lipid precursor. However, during the fatty acid chain elongation and ketoacyl reduction process, the host cell must consume an extremely large amount of the reducing cofactor—reduced nicotinamide adenine dinucleotide phosphate (NADPH). Therefore, from the perspective of metabolic flux balance, the biosynthesis of rhamnolipids is a typical complex metabolic accumulation process highly dependent on the supply of intracellular in-situ reducing power.
[0004] Currently, most domestic and international attempts to construct recombinant high-yield engineered strains of *Pseudomonas aeruginosa* focus on enhancing exogenous or endogenous direct synthase genes. Existing technologies typically employ strategies such as high-copy expression vectors and promoter engineering to increase the expression levels of the rhamnosyltransferase encoding gene *rhlAB* or the dTDP-L-rhamnose synthesis module *rmlBDAC*, thereby enhancing rhamnolipid biosynthesis. For example, patent CN115216505B increased rhlB expression using the PrpsJ strong promoter strategy, thereby increasing rhamnolipid yield to 35.34 g / L; patent CN113122556B achieved a fermentation yield of 838 mg / L in *E. coli* by constructing a dynamic expression system to regulate rhlAB expression; and patent CN113481140B increased rhamnolipid yield by inhibiting the expression of the *mexT* gene in *Pseudomonas aeruginosa*. Simultaneously, some studies have also explored ways to alleviate transcriptional limitations in the synthetic pathway and improve the efficiency of rhamnolipid synthesis by regulating quorum sensing systems and global transcriptional regulatory networks.
[0005] With the exponential increase in the expression levels of core genes directly catalyzing biosynthesis (such as the rhlAB module), the rate of downstream reactions consuming lipid precursors and associated NADPH reducing equivalents increases exponentially. However, the cofactor pool and in-situ regeneration rate within the host cell, originally used to maintain basic life activities, cannot keep up with such a high-intensity exogenous pull, resulting in a severe lag in the in-situ regeneration of intracellular NADPH. Existing genetically engineered bacteria modification schemes face obvious technical bottlenecks.
[0006] This implicit reducing power limitation forms a deep metabolic rate-limiting bottleneck. Especially when metabolism occurs via glycolysis and the tricarboxylic acid cycle (TCA) using carbon sources such as glycerol, there is a lack of sufficiently strong metabolic pathways to efficiently replenish NADPH. This directly leads to the core rate-limiting enzyme in fatty acid synthesis being in a "starved" state due to a lack of cofactors, unable to operate at full speed. Current technologies rely on strengthening terminal synthetic genes, ignoring the systemic bottleneck of upstream cofactor regeneration rates and the synergistic replenishment of precursor scaffolds. Furthermore, when analyzing *Pseudomonas aeruginosa* ATCC 9027 using whole-genome sequencing, the precise endogenous regulatory characteristics, transcriptional intensity limitations, and their functional synergistic behaviors in the synthesis of specific biosurfactants are completely unknown and unexplored in current technologies because many metabolic enzymes involved in oxidative decarboxylation and mediating reducing power allocation are based on computer-generated predictions (ProteinHomology predictions). In the original strain, these genes are subject to strict endogenous negative feedback or weak promoter transcriptional limitations, resulting in extremely low natural expression levels, making it impossible to spontaneously overcome the reducing power bottleneck. Summary of the Invention
[0007] The purpose of this invention is to overcome the shortcomings of the prior art and provide a recombinant *Pseudomonas aeruginosa* strain that produces high levels of rhamnolipids. This invention breaks away from the traditional approach of focusing solely on modifying terminal synthase genes, and for the first time, identifies a key endogenous reducing power regeneration target restricted by transcription—endogenous NADP—from the genome through automated predictive annotation. + This study utilizes a malic enzyme-dependent gene. By placing this endogenous gene under the regulation of a strong promoter for high-level exogenous expression, the host's natural transcriptional repression is broken. Without imposing growth penalties or disrupting basal cellular activity, it achieves highly efficient in-situ regeneration of intracellular reducing equivalents (NADPH) during fermentation and synergistically replenishes pyruvate to the acetyl-CoA precursor pool. Ultimately, this alleviates the reducing stress of fatty acid chain elongation and significantly enhances rhamnolipid production in the recombinant strain.
[0008] This invention provides a recombinant *Pseudomonas aeruginosa* strain that produces high levels of rhamnolipids, by overexpressing NADP in a starting strain of *Pseudomonas aeruginosa* capable of producing rhamnolipids. + The malate-dependent malate enzyme is encoded by the gene maeB.
[0009] In specific embodiments, strains of *Pseudomonas aeruginosa* capable of producing rhamnolipids that possess the following characteristics can also be used in principle in this invention:
[0010] (1) Pseudomonas aeruginosa or other Pseudomonas strains that have an endogenous rhamnolipid synthesis pathway, namely, Pseudomonas aeruginosa or other Pseudomonas strains carrying core genes for rhamnolipid synthesis such as rhlAB (rhamnosyltransferase) and rmlBDAC (dTDP-L-rhamnosyl synthesis module);
[0011] (2) Contains the endogenous NADP+-dependent malic acid enzyme encoding gene maeB or its functional homolog, which can achieve in situ regeneration of intracellular NADPH by overexpressing the gene;
[0012] Ideally, it should also possess (3) the ability to accept transformation with exogenous recombinant plasmids and stably express exogenous genes (i.e., to introduce broad-host shuttle plasmids such as pUCP24 via electroporation); and
[0013] (4) Under fermentation conditions, hydrophobic carbon sources such as vegetable oil (rapeseed oil, soybean oil, etc.) can be used as fermentation substrates for the production of rhamnolipin.
[0014] Specifically, *Pseudomonas aeruginosa* ATCC9027, or *Pseudomonas aeruginosa* PAO1 (GenBank accession number: GCA_000006765.1) can also be used as alternative host strains. However, it is important to note the strain-specific differences in rhamnolipin production and virulence among different strains. Although strain PA14 has a high rhamnolipin production, its strong virulence makes it unsuitable for industrial applications, and therefore, PA14 should not be selected from an industrial application perspective.
[0015] Specifically, NADP + The amino acid sequence of the maeB gene encoding malatease-dependent malate is shown in SEQ ID No:4.
[0016] More specifically, NADP + The nucleotide sequence of the malate-dependent malate enzyme encoding gene maeB is shown in SEQ ID No:3.
[0017] The overexpression is achieved through introduction via an expression vector, and the main considerations for overexpression are as follows:
[0018] 1. Expression vector selection – broad-host shuttle plasmids:
[0019] The pUCP24 plasmid (GenBank accession number: U07167.1) was used as the expression vector. This vector is an Escherichia-Pseudomonas shuttle vector, containing both the pMB1 replicon (for high copy number replication in E. coli, facilitating plasmid construction and mass production) and the pRO1600 replicon (for stable replication and maintenance in Pseudomonas), ensuring stable inheritance of the recombinant plasmid in Pseudomonas aeruginosa ATCC9027. The vector has a total length of 4036 bp and is a high copy number vector.
[0020] 2. Promoter Preferred Requirements – IPTG Induced Strong Promoters:
[0021] For example, the pUCP24 vector carries the Lac promoter (Plac) / lac operon system. This promoter is an IPTG (isopropyl-beta-D-thiogalactopyranoside) inducible strong promoter, which is repressed by the lacI repressor protein in the absence of IPTG. Upon addition of IPTG, IPTG binds to the lacI repressor protein, causing a conformational change and dissociation from the operator gene (lacO), allowing RNA polymerase to bind to the promoter and initiate high-level transcription of the maeB gene. During fermentation, the addition of IPTG (working concentration 0.5 mM) induces maeB gene expression, breaking the natural transcriptional repression of the maeB gene by the host's endogenous weak promoter. This inducible system allows cells to grow and multiply to a suitable density (OD600 approximately 0.6-0.8) before initiating high-level expression of the target gene, avoiding the metabolic burden on host growth caused by premature accumulation of exogenous proteins.
[0022] 3. Codon Requirements – No codon optimization required:
[0023] Since the maeB gene is an endogenous gene of *Pseudomonas aeruginosa* ATCC9027, its natural codon usage frequency is already fully adapted to the host tRNA pool and translation system, thus eliminating the need for any codon optimization or heterologous codon adaptation. This avoids common problems in heterologous expression (such as expressing *Pseudomonas* genes in *E. coli*), such as codon bias bottlenecks, translational stagnation, and protein misfolding. The maeB gene is obtained directly from the ATCC9027 genome via PCR amplification and inserted into the expression vector in its natural sequence form.
[0024] 4. Preferably, the marker selected is gentamicin resistance:
[0025] The pUCP24 vector carries the gentamicin acetyltransferase gene (aacC1, annotated as gentamycinacetyltransferase-3-1 in GenBank) as a positive and negative selection marker. During fermentation, gentamicin (working concentration 50.0 μg / mL) is used to maintain selection pressure, ensuring that the recombinant plasmid is not lost under antibiotic-free natural conditions and guaranteeing the stability of the plasmid during long-term fermentation culture (72-96 h) of the engineered strain.
[0026] 5. Cloning Strategies – Targeted Cloning and Homologous Recombination:
[0027] The PCR amplification primers for the target gene maeB were fitted with BamHI (forward primer) and HindIII (reverse primer) restriction endonuclease recognition sites at their 5' ends. The vector pUCP24, linearized by double digestion with BamHI and HindIII, was ligated to the maeB PCR product using homologous recombination (Hieff Clone Plus One Step Cloning Kit) to ensure the maeB gene was inserted into the vector's multiple cloning site (MCS) in the correct orientation and reading frame. The recombinant plasmid was verified by BamHI / HindIII double digestion (vector fragment 5481 bp, insert fragment 1269 bp) and confirmed by sequencing.
[0028] 6. Host transformation – Electroporation is the preferred method:
[0029] The recombinant plasmid pUCP24-maeB was introduced into *Pseudomonas aeruginosa* ATCC9027 competent cells via electroporation. Competent cells were prepared by washing repeatedly with 300 mM sucrose solution to remove salt. The electroporation parameters were 2.5 kV, 25 μF, and 200 Ω. Immediately after electroporation, cells were revived in preheated LB medium and plated on gentamicin selection plates. Positive transformants were verified by colony PCR and then stored in frozen glycerol tubes.
[0030] 7. Other considerations:
[0031] (1) Plasmid copy number: pUCP24 has a medium to high copy number in Pseudomonas, which is conducive to the high-level expression of the maeB gene.
[0032] (2) Promoter strength: The Lac promoter is a strong promoter that can achieve high-level transcription of the maeB gene, but it needs to be combined with the optimization of the IPTG induction timing to balance cell growth and product expression.
[0033] (3) Plasmid stability: Gentamicin selection pressure needs to be maintained continuously during long-term fermentation (96h) to prevent plasmid loss and subsequent decrease in expression level.
[0034] This invention also provides NADP + Application of the maeB gene, which encodes malate-dependent malate, in increasing the rhamnolipin production of Pseudomonas aeruginosa.
[0035] Specifically, it involves overexpressing NADP in *Pseudomonas aeruginosa*, a bacterium that produces rhamnolipids. + This is achieved through the maeB gene, which encodes a malate-dependent malate enzyme.
[0036] Specifically, NADP + The amino acid sequence of the maeB gene encoding malatease-dependent malate is shown in SEQ ID No:4.
[0037] More specifically, NADP + The nucleotide sequence of the malate-dependent malate enzyme encoding gene maeB is shown in SEQ ID No:3.
[0038] The present invention also provides a method for preparing rhamnolipin, which involves fermenting recombinant Pseudomonas aeruginosa as described above to produce rhamnolipin.
[0039] Furthermore, it also includes the step of separating the generated rhamnolipid.
[0040] The biosynthesis of rhamnolipids involves multiple metabolic processes, including central carbon metabolism, de novo fatty acid synthesis, and rhamnose precursor synthesis. In the de novo fatty acid synthesis, β-ketoacyl-ACP is converted to β-hydroxyacyl-ACP under the catalysis of β-ketoacyl-ACP reductase (FabG), with each reduction reaction consuming one molecule of NADPH. As the fatty acid carbon chain elongates, this reduction reaction continues in a cycle, resulting in a sustained consumption of large amounts of NADPH during fatty acid synthesis. Simultaneously, in the synthesis of dTDP-L-rhamnose, dTDP-4-keto-6-deoxy-L-mannose is converted to dTDP-L-rhamnose under the catalysis of dTDP-4-dehydrorhamnose reductase (RmlD), also requiring one molecule of NADPH per reaction. Subsequently, β-hydroxyacyl-ACP and dTDP-L-rhamnose, acting as lipid and glycosyl precursors respectively, complete the synthesis of rhamnolipids under the catalysis of key enzymes such as RhlA, RhlB, and RhlC. Therefore, the intracellular NADPH supply capacity directly affects the formation of rhamnolipid precursors and the accumulation of final products. Existing technologies mainly increase rhamnolipid production by overexpressing rhamnolipid synthesis-related genes such as rhlAB or by using promoter engineering to enhance their expression levels. However, as the expression intensity of the synthetic pathway continuously increases, the demand for NADPH from downstream metabolism rapidly increases, while the host cell's endogenous NADPH regeneration capacity is difficult to increase simultaneously, making intracellular reducing power supply a crucial factor limiting further accumulation of rhamnolipids. Therefore, relying solely on strengthening the rhamnolipid synthesis pathway is insufficient to fundamentally overcome the technical bottleneck in constructing high-yield engineered bacteria. Based on the above analysis, the inventors systematically studied the central metabolic network of *Pseudomonas aeruginosa* ATCC9027 and ultimately selected the NADP⁺-dependent malate enzyme encoding gene *maeB*, located at a key node in the tricarboxylic acid cycle, as the engineering target. Through experimental research and verification, this invention was finally completed. The rhamnolipin production of the recombinant strain was significantly increased from 3.52±0.09 g / L of the original strain to 4.97±0.23 g / L in 200 mL shake flask fermentation.
[0041] This invention uses NADP + The maelase-encoding gene *maeB* was used as an engineering target to construct high-yield rhamnolipin-producing engineered bacteria. By constructing *maeB*-overexpressing engineered bacteria, the in-situ regeneration capacity of intracellular NADPH was enhanced, continuously providing reducing equivalents for fatty acid synthesis and dTDP-L-rhamnose synthesis. Simultaneously, it promoted the carbon flow allocation from central carbon metabolism to the fatty acid synthesis pathway, thereby synergistically enhancing the supply of rhamnolipin precursors and increasing rhamnolipin fermentation yield. This differs from existing techniques that primarily target rhamnolipin synthesis structural genes (rhlAB / rmlBDAC), instead offering a novel metabolic engineering strategy for increasing rhamnolipin production by addressing the host cell's reducing power metabolic balance.
[0042] Secondly, this invention also relates to a synergistic mechanism of reducing power and carbon flow and its application in rhamnolipid production. This invention discloses and utilizes NADP. + The unique "reducing power-carbon flux synergistic" mechanism of action of malate-dependent malate enzyme maeB in Pseudomonas aeruginosa: maeB catalyzes the oxidative decarboxylation of L-malate to pyruvate, which is then specifically coupled to generate NADPH (malate + NADP). + →pyruvate+CO2+NADPH), this reaction simultaneously achieves two independent and complementary synergistic pathways within the cell—(1) In-situ regeneration of reducing power: directly supplying NADPH to the FabG-catalyzed β-ketoacyl-ACP reduction reaction in de novo fatty acid synthesis and the RmlD-catalyzed reduction reaction in dTDP-L-rhamnose synthesis, thus relieving the "starvation" bottleneck of reducing equivalents that occurs after the end synthesis is enhanced; (2) Precursor carbon skeleton replenishment: the reaction product pyruvate enters the acetyl-CoA pool, directionally replenishing the carbon skeleton required for fatty acid synthesis, and synergistically promoting the carbon flow distribution from central carbon metabolism to lipid precursors. The two pathways are coupled at a single target point, forming a "reducing power-carbon flow dual-effect synergy", which enables downstream precursor substances to simultaneously gain in both reducing power and carbon skeleton dimensions. This is a technical effect that conventional end-enhancing strategies in this field cannot achieve simultaneously. The synergistic mechanism of this dual effect was directly confirmed by the fermentation results: at the 200 mL shake flask level, the rhamnolipin yield of the recombinant strain ATCC9027 / maeB reached 4.97±0.23 g / L (wild type 3.52±0.09 g / L, an increase of 41.2%), and the apparent yield Yp / s increased from 0.235 to 0.331 g·g⁻¹. -1 Under scale-up conditions in a 5.0L fermenter, the yield reached 50.95±3.74 g / L (compared to 39.74±2.96 g / L for the wild type, representing a 28.2% increase), and Yp / s increased from 0.530 to 0.679 g·g. -1 The simultaneous, order-of-magnitude increase in yield and substrate-product conversion rate at both scales aligns with the characteristics of "dual unlimitation of reducing power and carbon flux" rather than "single end-product capacity scaling up." Based on the above mechanism, this invention also provides the use of the recombinant *Pseudomonas aeruginosa* in the fermentation production of rhamnolipids. Taking rapeseed oil or soybean oil as the initial fermentation substrate, inoculated at a 5% (v / v) inoculum, fermented at 37°C with 0.5 mM IPTG and 50.0 μg / mL gentamicin for 72-96 h, the recombinant strain can stably achieve high yields of rhamnolipids (≥4.97 g / L in shake flasks, ≥50.95 g / L in fermenters) under shake flask and 5.0 L fermenter scale-up conditions, with an apparent substrate-product yield of not less than 0.679 g·g⁻¹. -1 It exhibits good scale-up fermentation performance and process stability. Attached Figure Description
[0043] Figure 1 The image shows a gel electrophoresis result of genome extraction.
[0044] Figure 2 For NADP + Gel electrophoresis image of maeB, the gene encoding malatease-dependent malatease.
[0045] Figure 3 To overexpress NADP + Map of the pUCP24-maeB plasmid, a recombinant expression plasmid for the malic acid oxidase-dependent gene.
[0046] Figure 4 To overexpress NADP + Electrophoresis image of the recombinant expression plasmid pUCP24-maeB, which encodes the malic acid oxidase-dependent gene, after double digestion.
[0047] Figure 5 Image of PCR gel electrophoresis of Pseudomonas aeruginosa colonies electroporated with the recombinant expression plasmid pUCP24-maeB.
[0048] Figure 6 The starting strain *Pseudomonas aeruginosa* ATCC9027 (CK group) in Example 2 of this invention and the overexpression of endogenous NADP + A comparison of rhamnolipid fermentation yields during 72 hours of fermentation in a 500 mL shake flask using the recombinant engineered strain ATCC9027 / maeB with a malicase-dependent gene.
[0049] Figure 7 The starting strain *Pseudomonas aeruginosa* ATCC9027 (CK group) in Example 2 of this invention and the overexpression of endogenous NADP + A comparison of rhamnolipid fermentation yields during fermentation in a 5.0L fermenter by the recombinant engineered strain ATCC9027 / maeB containing the malic acid oxidase gene. Detailed Implementation
[0050] The culture media used for Pseudomonas aeruginosa fermentation include:
[0051] LB medium: 5.0 g / L yeast extract, 10.0 g / L tryptone, 10.0 g / L NaCl, pH=7.0±0.1.
[0052] Shake-flask fermentation medium: 3.9 g / L KNO3, 1.0 g / L NaCl, 1.0 g / L KCl, 0.05 g / L CaCl2, 3.5 g / L KH2PO4, 1.4 g / L Na2HPO4, 0.6 g / L MgSO4·7H2O, 0.001 g / L FeSO4·7H2O, 15.0 g / L rapeseed oil, 2 ml / L trace elements, pH=7.0±0.1.
[0053] Small-scale fermentation medium: 3.9 g / L KNO3, 1.0 g / L NaCl, 1.0 g / L KCl, 0.05 g / L CaCl2, 3.5 g / L KH2PO4, 1.4 g / L Na2HPO4, 0.6 g / L MgSO4·7H2O, 0.001 g / L FeSO4·7H2O, 75.0 g / L soybean oil, 2 ml / L trace elements, pH=7.0±0.1.
[0054] In this invention, "malic enzyme" refers to endogenous NADP. + Malate-dependent enzyme encoding gene. pUCP24: A broad-host recombinant expression plasmid containing a gentamicin resistance marker, suitable for Pseudomonas spp. CK: The original starting strain of Pseudomonas aeruginosa ATCC9027 without any genetic engineering modifications.
[0055] Example 1: Construction of recombinant Escherichia coli overexpressing maeB
[0056] I. Extraction of the target gene:
[0057] Total genomic DNA was extracted from *Pseudomonas aeruginosa* ATCC9027 using a bacterial genomic DNA extraction kit. *Pseudomonas aeruginosa* ATCC9027 is a typical Gram-negative bacterium; therefore, the extraction method followed the Gram-negative bacterial total DNA extraction method described in the kit. The electrophoresis results for the total genomic DNA of *Pseudomonas aeruginosa* ATCC9027 are shown below. Figure 1 As shown.
[0058] Using the genome of *Pseudomonas aeruginosa* ATCC9027 as a template, the target gene fragment *maeB* was amplified by PCR using primers *maeB-F* and *maeB-R* (GenBank accession number: GCA_001402955.1). The fragment size was 1326 bp. Agarose gel electrophoresis was performed as follows: Figure 2 As shown, the primer sequences used are as follows.
[0059] maeB-F: gagctcggtacccggggatccAGCGGAAGTGCCCAAATGT (SEQ ID No: 1)
[0060] maeB-R: acgacggccagtgccaagcttTCAGCCGTTGAAGACGTCATC (SEQ ID No: 2).
[0061]
[0062] Reaction program: 95℃ pre-denaturation for 3 min; 35 cycles: 95℃ denaturation for 15 s, 60℃ annealing for 15 s, 72℃ extension for 1 min; 72℃ complete extension for 5 min.
[0063] The PCR product fragments were then purified using a PCR product purification and recovery kit (Sangon Biotech Co., Ltd.) after agarose gel electrophoresis and used for subsequent ligation.
[0064] The nucleotide sequence of the maeB gene is as follows (SEQ ID No: 3):
[0065] The amino acid sequence encoded by the maeB gene is as follows (SEQ ID No: 4): MSDLKTAALEYHAQPRPGKLSVELTKPTATARDLSLAYSPGVAEPVREIARDAELAYQYTGKGNLVAVISDGTAILGLGNLGPLASKPVMEGKGVLFKRFAGIDVFDIEVDAESPQAFIDTVKRISITFGGINLEDIKAPECFEIERALIEQCDIPVFHDDQHGTAIVTAAGMLNALELAGKKLEDAKIVCLGAGAAAISCMKLLVSMGAK VENIYMIDRKGVIHAGRDDLNQYKSVFATETDKRTLADALDGADVFVGLSGANLLEPEDLKRMAPNPIVFACSNPDPEIKPELAHATRNDVIMATGRSDYPNQVNN VLGFPFIFRGALDVRATRINEEMKIAAALALRDLAKQPVPEDVCAAYGVDKLEFGREYIIPKPMDKRLISVVSDAVAKAAIETGVATLPYPKNYPLKSVDDVFNG.
[0066] II. Construction of recombinant plasmids:
[0067]
[0068] The enzyme digestion products were purified and recovered using the FastPure Gel DNA Extraction Mini Kit (Nanjing Novizan Biotechnology Co., Ltd.).
[0069] The purified PCR product fragment of the maeB gene and the purified linearized vector were ligated using the Hieff ClonePlus One Step Cloning Kit (Yisheng Biotechnology Co., Ltd.). The system consisted of 20 μL of vector (50–200 ng) and insert fragment (20–200 ng). The vector volume used in the recombination reaction was 0.03 pmol. The fragment was added at a molar ratio of gene fragment to vector fragment of 3:1. 10.0 μL of 2×Hieff CloneEnzyme Premix was added, and ddH2O was added to bring the total volume to 20.0 μL. The reaction was carried out at 37°C for 20 min. The recombinant plasmid map is shown below. Figure 3As shown. After the reaction, the ligation product was transformed into E. coli DH5α competent cells: ice bath for 30 min, heat shock at 42℃ for 90 s, ice bath again for 5 min, cultured on a shaker at 37℃ for 1 h, and then the transformation product was plated on LB plates containing gentamicin resistance and cultured overnight at 37℃.
[0070] Positive transformants were selected and inoculated into LB medium containing gentamicin resistance. The cultures were incubated overnight at 37°C and 200 rpm. Plasmids were extracted using a plasmid mini-extraction kit (Tiangen Biotech Co., Ltd.). The plasmids were validated by double digestion with BamHI and HindIII. The validation results are shown below. Figure 4 As shown, the plasmid fragment is 5481 bp, the enzyme digestion fragment is 1269 bp, and the recombinant plasmid is named pUCP24-maeB.
[0071] Example 2: Construction of recombinant ATCC9027 overexpressing maeB
[0072] The bacterial culture was cultured at 37°C with shaking until mid-log growth (OD600 approximately 0.6-0.8). After pre-cooling on ice, the cells were harvested by centrifugation at 4°C and 4000 rpm for 10 min. The supernatant was then discarded, and the cells were gently resuspended in an equal volume of pre-cooled analytical grade 300 mM sucrose solution. The cells were then centrifuged and washed 2 to 3 times, with the washing volume gradually reduced to thoroughly remove residual salts. Finally, the cells were resuspended at 1 / 100 of the original volume and aliquoted into competent cells. During transformation, 100 μL of competent cells were mixed with 1 μg pUCP24-maeB plasmid and transferred into a pre-cooled 0.2 cm electroporation cuvette. Electroporation was performed at parameters of 2.5 kV, 25 μF, and 200 Ω. Immediately after electroporation, 1 mL of preheated LB medium was added and mixed well. The cells were then cultured at 37°C and 200 rpm for 1 h with shaking. Finally, the cells were centrifuged, concentrated, and plated onto gentamicin antibiotic screening plates. The plates were then incubated upside down at 37°C for 24 h.
[0073] Colony PCR Validation: Single colonies were picked for colony PCR validation. The colony PCR system was 20 μL: a single colony was picked with a pipette tip, 10 μL of 2×Rapid Taq Master Mix was added, and ddH2O was added to bring the volume to 20 μL. The colony PCR primers are as follows:
[0074] pUCP24-F: GTCGATGTTTGATGTTATGGAGC (SEQ ID No: 5)
[0075] pUCP24-R:GTGGTCCTGCAACTTTATCC (SEQ ID No: 6).
[0076] Colony PCR program: 95℃ pre-denaturation for 3 min; 30 cycles: 95℃ denaturation for 15 s, 60℃ annealing for 15 s, 72℃ extension for 1 min; 72℃ final extension for 5 min. Colony PCR results are as follows: Figure 5 As shown, positive transformants were selected, inoculated into gentamicin-resistant LB medium for expansion, and frozen glycerol tubes were stored.
[0077] Example 3: Fermentation of recombinant Pseudomonas aeruginosa and determination of rhamnolipid concentration
[0078] I. Seed culture:
[0079] Recombinant Pseudomonas aeruginosa and wild-type bacteria were inoculated into LB medium and cultured overnight at 37°C in a shaker to serve as seed culture solutions.
[0080] II. Shake-flask fermentation culture: The seed culture obtained above was inoculated into a 500 mL Erlenmeyer flask containing 200.0 mL of fermentation medium at an inoculation rate of 5%. The recombinant strain was added with IPTG (working concentration 0.5 mM) and gentamicin (working concentration 50.0 μg / mL) and fermented at 37℃ and 200 rpm for 72 h. Rhamnose lipid content was measured every 12 h during the fermentation process.
[0081] III. Small-scale fermentation culture: The seed culture obtained above was inoculated into a 5.0L fermenter containing 2.5L of fermentation medium at an inoculation rate of 5% (v / v). IPTG (working concentration 0.5mM) and gentamicin (working concentration 50.0μg / mL) were added to the recombinant strain fermentation system. The initial fermentation pH was set to 7.0, the culture temperature to 37℃, the stirring speed to 800rpm, and the aeration rate to 1.5L / min. Fermentation was carried out under the above conditions for 96h. Samples were taken every 12h during fermentation to determine the rhamnolipid content in the fermentation broth.
[0082] IV. Extraction of rhamnolipin from fermentation broth:
[0083] Take 100.0 μL of the above fermentation broth and adjust the pH to 2.0 with hydrochloric acid; add 300.0 μL of ethyl acetate and extract with shaking for 10 min, then centrifuge at 12000 rpm for 5 min after extraction; aspirate the organic phase, add another 300.0 μL of ethyl acetate and extract for 10 min, then centrifuge at 12000 rpm for 5 min after extraction; aspirate the organic phase again and combine the two aspirated organic phases, then place them under a nitrogen blower to volatilize the organic phase. After the ethyl acetate has completely volatilized, add 100.0 μL of H2O to the centrifuge tube, shake and mix well, and use this as the sample to be tested.
[0084] V. Determination of rhamnolipid concentration:
[0085] Accurately pipette 1.0 ml of standard solutions with concentrations of 0.4, 0.2, 0.12, 0.08, 0.06, and 0.024 mg / mL, as well as 1.0 ml of the fermentation broth sample diluted 40-80 times, into separate reaction tubes. Pre-cool all reaction tubes by immersing them in an ice-water bath. While in the ice-water bath, slowly add 4.0 ml of 0.2% w / v anthrone sulfate solution to each tube, quickly shaking to mix and prevent localized overheating. After sample addition, immediately transfer the reaction tubes to a boiling water bath and heat for 15 min, ensuring the tube openings are tightly sealed to prevent water evaporation. After the 15 min mark, quickly return the tubes to the ice-water bath and cool for 20 min to completely terminate the reaction. Measure the absorbance at 620 nm and calculate the actual concentration of rhamnolipin in the sample using the formula derived from the simultaneously measured standard curve, based on the dilution factor.
[0086] The results of rhamnolipid assay are as follows: Figure 6 and Figure 7 As shown: Under 200 mL shake flask fermentation conditions, overexpression of endogenous NADP + The recombinant strain ATCC9027 / maeB, which encodes the malate-dependent enzyme gene (maeB), achieved a rhamnolipin fermentation yield of 4.97 ± 0.23 g / L, which was 1.41 times that of the wild-type ATCC9027 (3.52 ± 0.09 g / L), representing a 41.2% increase compared to the wild-type. Using 15 g / L rapeseed oil as the initial fermentation substrate, the apparent yield (Yp / s) of rhamnolipin from the recombinant strain reached 0.331 g·g⁻¹. -1 It is 0.235 g·g higher than that of the wild type. -1 .
[0087] VI. Small-scale fermentation in a 5L fermenter
[0088] The specific conditions for the small-scale fermentation in a 5L fermenter are as follows:
[0089] 1. Composition of fermentation medium (small-scale fermentation medium):
[0090] 3.9 g / L KNO3, 1.0 g / L NaCl, 1.0 g / L KCl, 0.05 g / L CaCl2, 3.5 g / L KH2PO4, 1.4 g / L Na2HPO4, 0.6 g / L MgSO4·7H2O, 0.001 g / L FeSO4·7H2O, 75.0 g / L soybean oil (as initial fermentation carbon source / substrate), 2 ml / L trace element solution, initial pH 7.0 ± 0.1.
[0091] 2. Fermentation process parameters:
[0092] Fermentation tank specifications: 5.0L mechanically stirred fermentation tank
[0093] Liquid volume (working volume): 2.5L
[0094] Inoculation amount: 5% (v / v), inoculate the seed culture (LB medium, overnight culture at 37°C) into the fermentation medium at a volume ratio.
[0095] Initial fermentation substrate: 75.0 g / L soybean oil
[0096] Inducer: IPTG (isopropyl-beta-D-thiopyranoside), working concentration 0.5 mM (recombinant strain)
[0097] Selective stress: Gentamicin, working concentration 50.0 ug / mL (recombinant strain)
[0098] Incubation temperature: 37℃
[0099] Initial pH: 7.0
[0100] Mixing speed: 800 rpm
[0101] Ventilation rate: 1.5 L / min
[0102] Fermentation cycle: 96 hours
[0103] Sampling frequency: Samples were taken every 12 hours to determine the rhamnolipin content in the fermentation broth.
[0104] 3. Fermentation process description:
[0105] Recombinant Pseudomonas aeruginosa ATCC9027 / maeB and wild-type ATCC9027 (CK control group) were inoculated into 5.0L fermenters containing 2.5L of pilot-scale fermentation medium and cultured for 96 hours under the above conditions. IPTG (0.5mM) and gentamicin (50.0μg / mL) were added to the fermentation system of the recombinant strain to induce maeB gene overexpression and maintain plasmid stability. No IPTG or gentamicin was added to the wild-type control group. Samples were taken every 12 hours during fermentation, and rhamnolipid concentration was determined using the ethyl acetate extraction-anthrone sulfate colorimetric method (620nm wavelength).
[0106] Under small-scale conditions in a 5L fermenter, the rhamnolipin yield of the recombinant strain ATCC9027 / maeB reached 50.95±3.74 g / L, significantly higher than the 39.74±2.96 g / L of the wild-type ATCC9027, representing 1.28 times that of the wild-type and an increase of 28.2% compared to the wild-type. Using 75.0 g / L soybean oil as the initial fermentation substrate, the apparent yield (Yp / s) of rhamnolipin from the recombinant strain reached 0.679 g·g⁻¹. -1 It is 0.530 g·g higher than that of the wild type. -1 .
[0107] Fermentation results showed that overexpression of endogenous NADP... + The malate-dependent enzyme encoding the gene *maeB* effectively enhances the in-situ regeneration of intracellular NADPH, improves the reducing power supply during fatty acid synthesis and rhamnose precursor formation, and promotes the biosynthesis and accumulation of rhamnolipids. Whether under shake-flask culture or scale-up culture conditions in a 5.0L fermenter, the recombinant strain exhibited superior rhamnolipid production capacity compared to the wild-type strain, indicating that the engineered strain constructed in this invention possesses excellent scale-up fermentation performance and process stability. This provides a novel metabolic engineering strategy for achieving efficient biomanufacturing of rhamnolipids by enhancing host reducing power metabolism.
[0108] In summary, this invention provides a method for increasing rhamnolipid production by enhancing intracellular reducing power metabolism in *Pseudomonas aeruginosa*. This is achieved through overexpression of endogenous NADP. + The malate-dependent enzyme encoding gene (maeB) effectively enhanced the in-situ regeneration capacity of intracellular NADPH, promoting the formation and accumulation of rhamnolipin precursors, thereby significantly increasing rhamnolipin fermentation yield. This method achieves yield improvement without altering the structural genes of the rhamnolipin synthesis pathway, providing a novel metabolic engineering strategy for constructing high-yield rhamnolipin engineered bacteria. It also serves as a reference for other NADPH-dependent biosynthetic processes and the modification of related engineered strains.
[0109] It should be understood in particular that the expression vectors, promoters, host strains, screening markers, culture conditions, and fermentation process parameters involved in this invention can all be appropriately adjusted or implemented using equivalent substitution methods known in the art, as long as they adopt the technical concept of this invention to increase rhamnolipid production by enhancing the intracellular reducing power metabolism of the host.
[0110] Therefore, any equivalent substitutions, transformations, or obvious improvements made to this invention based on the technical content disclosed in the specification and claims should be included within the scope of protection of this invention. The scope of protection of this invention should be determined by the claims, and should not be limited solely to the specific embodiments described in the specification.
Claims
1. A recombinant *Pseudomonas aeruginosa* strain that produces high levels of rhamnolipids, characterized in that, It overexpresses NADP in the original strain of *Pseudomonas aeruginosa*, which can produce rhamnolipids. + The malate-dependent malate enzyme is encoded by the gene maeB.
2. The recombinant Pseudomonas aeruginosa as described in claim 1, characterized in that, The Pseudomonas aeruginosa strain that produces rhamnolipids has an endogenous rhamnolipid synthesis pathway and contains the endogenous NADP+-dependent malate enzyme encoding gene maeB or its functional homolog, which can achieve in situ regeneration of intracellular NADPH by overexpressing this gene. Specifically, it is Pseudomonas aeruginosa ATCC9027.
3. The recombinant Pseudomonas aeruginosa as described in claim 1, characterized in that, NADP + The amino acid sequence of the maeB gene encoding malatease-dependent malate is shown in SEQ ID No:
4.
4. The recombinant Pseudomonas aeruginosa as described in claim 3, characterized in that, NADP + The nucleotide sequence of the maeB gene encoding malatease-dependent malate is shown in SEQ ID No:
3.
5. NADP + Application of the maeB gene, which encodes malate-dependent malate, in increasing the rhamnolipin production of Pseudomonas aeruginosa.
6. The application as described in claim 5, characterized in that, It involves overexpressing NADP in *Pseudomonas aeruginosa*, a bacterium that produces rhamnolipids. + This is achieved through the maeB gene, which encodes a malate-dependent malate enzyme.
7. The application as described in claim 6, characterized in that, The Pseudomonas aeruginosa that produces rhamnolipids is Pseudomonas aeruginosa ATCC9027.
8. The application as described in claim 7, characterized in that, NADP + The amino acid sequence of the maeB gene encoding malatease-dependent malate is shown in SEQ ID No:
4.
9. A method for preparing rhamnolipid, characterized in that, It is a step of producing rhamnolipids by fermenting the recombinant Pseudomonas aeruginosa as described in any one of claims 1 to 4.
10. The method as described in claim 9, characterized in that, It also includes the step of separating the generated rhamnolipid.
Citation Information
Patent Citations
Oscillatory gene expression system, construction method and its application in rhamnolipid fermentation
CN113122556B
